Nevirapine Generics [uk]

Nevirapine, the active ingredient in Nevirapine Generics, is a non‑nucleoside reverse transcriptase inhibitor presented as an oral tablet for oral use. It is employed in combination regimens to treat HIV‑1 infection in adults and children, helping to suppress viral replication. The drug works by binding to a specific site on the HIV‑1 reverse transcriptase enzyme, causing a conformational change that blocks its activity. This class of medication is a cornerstone of highly active antiretroviral therapy (HAART).

GNH USA supplies Nevirapine Generics as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nevirapine is used as part of antiretroviral therapy to inhibit HIV‑1 replication. - HIV‑1 infection (adults): when added to a combination of nucleoside reverse transcriptase inhibitors, it lowers plasma HIV‑1 RNA levels and helps maintain immune function. - HIV‑1 infection (children): incorporated into pediatric antiretroviral regimens, it contributes to sustained viral suppression and CD4 count improvement. - Treatment‑experienced HIV‑1 infection: offers an alternative NNRTI backbone for patients who have experienced virologic failure with other agents. - HIV‑1 infection (initial therapy): recommended as part of a first‑line regimen combined with two nucleoside reverse transcriptase inhibitors to achieve early viral suppression.

Nevirapine may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Rash: mild to moderate skin redness, often transient. - Nausea: feeling of stomach upset, may be accompanied by vomiting. - Fatigue: generalized tiredness that can affect daily activities. - Headache: mild to moderate pain in the head region. - Abdominal pain: discomfort or cramping in the stomach area. - Dizziness: sensation of light‑headedness or unsteadiness.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin reactions with blistering and detachment. - Severe hepatic injury or hepatitis: marked elevation of liver enzymes, jaundice, or liver failure. - Hypersensitivity reactions with fever and eosinophilia: systemic allergic response requiring immediate discontinuation. - Neutropenia or severe anemia: significant reduction in white blood cells or red blood cells. - Grade 3–4 elevated liver enzymes: substantial increase in ALT/AST indicating liver stress. - Drug‑induced lung injury: rare pulmonary toxicity presenting with cough and dyspnea.

When prescribing nevirapine, clinicians should observe several safety precautions to minimize risk. - Liver monitoring: check baseline hepatic enzymes and repeat regularly during therapy. - Rash surveillance: inspect skin frequently and discontinue if severe rash develops. - Hypersensitivity watch: be alert for fever, malaise, or eosinophilia indicating allergic reaction. - Drug interactions: avoid co‑administration with strong CYP3A4 inducers that lower nevirapine levels. - Pregnancy considerations: use only if benefits outweigh potential risks, after specialist assessment. - Store at ambient temperature: keep tablets in the original container, protect from moisture and direct sunlight.

Nevirapine interacts with several medicines; understanding the interaction level guides clinical management.

Major Interactions (Avoid): - Rifampicin: induces CYP3A4, markedly reducing nevirapine exposure. - St. John’s wort: strong CYP3A4 inducer that can lead to therapeutic failure. - Protease inhibitors (e.g., ritonavir): increase nevirapine levels and risk of hepatotoxicity. - Carbamazepine: enzyme inducer that lowers nevirapine concentrations. - Efavirenz: concurrent NNRTIs can cause additive toxicity.

Moderate Interactions (Monitor Closely): - Azole antifungals (ketoconazole, fluconazole): may increase nevirapine plasma levels. - Macrolide antibiotics (erythromycin, clarithromycin): can affect metabolism modestly. - Oral contraceptives: nevirapine may reduce hormonal efficacy, requiring backup contraception. - Warfarin: potential alteration of anticoagulant effect, monitor INR. - Methadone: nevirapine may lower methadone levels, assess withdrawal symptoms.